Once absorbed into the body, epichlorohydrin is metabolized primarily in the liver. It undergoes enzymatic conversion to form 3-chloro-1,2-propanediol and its conjugates. These metabolites may contribute to the compound's toxic effects, including its potential role in carcinogenesis. Understanding the metabolic pathways is key to assessing the risk and developing appropriate safety measures.
